<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Neurosciences</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A23C0CE5-E7E7-4090-8D5C-C4944BA70F86"><gtr:id>A23C0CE5-E7E7-4090-8D5C-C4944BA70F86</gtr:id><gtr:firstName>Johnathan</gtr:firstName><gtr:surname>Cooper-Knock</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK003771%2F1"><gtr:id>4A29180D-9465-4272-8E6D-BAF094D2BBA4</gtr:id><gtr:title>Characterisation of biological pathways dysregulated in amyotrophic lateral sclerosis (ALS) cases with a hexanucleotide repeat expansion of C9ORF72.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K003771/1</gtr:grantReference><gtr:abstractText>Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and tragic neurodegenerative condition. It has been recently been discovered that an expansion of the gene C9ORF72 causes a relatively large proportion of ALS. The function of C9ORF72 in disease and health is currently unknown. The aim of this project is to determine disease mechanisms associated with the C9ORF72 expansion. This will be a major advance towards the development of therapeutic agents for ALS more widely.
 
In order to become functional, genes (as DNA) must be expressed in a RNA form. It has been postulated that the C9ORF72 expansion causes disease by disruption of the assembly of RNA in the cell nucleus. This is supported by pilot work carried out by the applicant. The ideal method for studying a disease of RNA assembly is gene expression profiling (GEP); this is a technique which measures the levels of various species of RNA in a sample. GEP will be carried out on post-mortem tissue from C9ORF72 patients and controls within our locally held tissue bank; and on cells from the blood of C9ORF72 patients and controls obtained from the MNDA National DNA bank and associated lymphoblastoid cell line (LCL) resource. Furthermore technology specialised for identifying misassembled RNA will be applied to skin cells from C9ORF72 patients and controls within our locally held biobank; this will be carried out in the MRC High-Throughput Sequencing (HTS) hub in Liverpool (see letter of support). The identity of samples with the C9ORF72 expansion within the MNDA National DNA bank and associated LCL resource will be obtained through collaboration with Professor Al-Chalabi (see letter of support). This resource contains a large number of samples and therefore is suitable for a GEP study, not only of patients with the C9ORF72 expansion but of such patients with either rapidly progressive or slowly progressive disease. This may facilitate the discovery of modifiers of disease which are potential therapeutic targets. The presence of disease modifiers is supported pilot work by the applicant showing that disease associated with the C9ORF72 expansion is significantly variable. Data about DNA changes in the same group of patients has already been obtained through collaboration with Professor Al-Chalabi and will be correlated with the GEP data. Thus disease modifiers will be understood at the DNA and the RNA level.
 
A modifier of disease associated with C9ORF72 which has aready been proposed is the size of the expansion which has been shown to be variable between patients. This is a significant disease modifier in other similar diseases. The expansion will be sized using DNA samples from the MNDA National DNA bank using a technique called Southern blotting. The relationship between the size of the expansion and various aspects of disease such as survival time will be examined.

Cell models are a useful tool for studying disease mechanisms. As well as being used in GEP skin cells from patients with the C9ORF72 expansion will be studied independently to determine how they differ to skin cells from controls. This technique has been used successfully in the study of ALS and other neurological diseases. This will be guided in part by the results of the other analyses described above to provide a validation of those discoveries. Another observation about C9ORF72 ALS is that the protein encoded by the C9ORF72 gene is present at a reduced concentration in patients with the expansion. This may be an additional disease mechanism co-existing with an effect on RNA assembly. This will be investigated by observing the effect of preventing expression of the C9ORF72 protein in a model consisting of nerve cells grown in the lab.

This work will be carried out primarily by the applicant but with assistance from the Functional Genomics, Computational Biology and Cell Biology teams within SITraN (Sheffield Institute for Translational Neuroscience).</gtr:abstractText><gtr:technicalSummary>Amyotrophic lateral sclerosis (ALS) is often rapidly progressive and tragic. A hexanucelotide repeat expansion within intron-1 of C9ORF72 has been discovered in a relatively large proportion of ALS. It is now possible to study a large group of ALS patients with a homogeneous disease mechanism. The function of C9ORF72 in disease and health is currently unknown, understanding this will be a major advance in deducing disease mechanisms and developing therapeutic agents. 
It is postulated that the expansion causes disease via sequestration of RNA splicing factors to the RNA form of the expansion and disruption of mRNA splicing. Pilot work demonstrated disruption of RNA splicing in C9ORF72 patients. The ideal method for study of a RNA mediated disease with an effect on RNA splicing is gene expression profiling (GEP). GEP using using U133 Plus 2.0 GeneChips will be carried out in laser captured motor neurons from post-mortem samples and a larger number of lymphoblastoid cell lines (LCL) from C9ORF72 patients and controls. RNA sequencing will be carried out on fibroblasts from C9ORF72 patients and controls; this is optimal for understanding aberrant splicing. Fibroblasts will also be used to conduct functional studies of C9ORF72 ALS and validate GEP findings.
Pilot work demonstrated variability in the phenotype associated with C9ORF72 ALS consistent with disease modifiers. Discovery of modifiers will contribute to understanding of pathogenesis. The expansion will be sized by Southern blotting in a large number of patients to determine how repeat length affects the disease phenotype. GEP in C9ORF72 patients with rapid and slowly progressive disease will be used to identify additional disease modifiers; this will be correlated with single nucleotide polymorphism data.
We and others have demonstrated reduced levels of C9ORF72 in peripheral and central nervous tissue from C9ORF72 patients. This will be investigated with siRNA mediated knockdown of C9ORF72 in SH-SY5Y cell</gtr:technicalSummary><gtr:potentialImpactText>Persons who will benefit from this research are:
- Patients suffering from amyotrophic lateral sclerosis (ALS) will experience societal benefit over the next 3-5 years from this project as the discovery of dysregulated biological pathways in ALS associated with expansion of C9ORF72 is a significant step towards the development of therapeutic agents. In addition, because there are common mechanisms of neuronal injury between ALS and other neurodegenerative diseases, the work of this project may, over a longer time-scale, help in the elucidation of molecular mechanisms of disease in neurodegenerative disorders more widely.
- Patients with ALS will also experience societal benefit from the identification of disease modifiers in ALS. Disease modifiers may become therapeutic targets; in addition the identification of phenotypic subgroups will allow better estimation of prognosis. Furthermore, awareness of phenotypic subgroups may reduce confounding factors in clinical trials, thereby enhancing the probability of developing robust disease modifying therapies and improving economic efficiency.
- Drug development companies may experience economic benefit from the outputs of this project over the next 5-10 years because a better understanding of disease pathogenesis in ALS and of disease modifiers will facilitate the design of novel therapeutic agents. The successful development and marketing of a therapeutic agent for ALS by a British drug company would have a significant economic impact and indirectly increase the tax revenue paid to the United Kingdom government. Additionally, such work has the potential to attract investment from global business partnerships.
- Efforts made to communicate the results of this research to the wider public both during and after the project has completed will have substantive societal impact by increasing public engagement with research. 
- Further economic and societal impact of this project is that by investing in a new and exciting area of translational research into neurodegenerative disease the funders would be most efficiently enabling follow-on investment and impact, bridging the gap identified by the government 'Strategy for UK Life Sciences'. The C9ORF72 genetic variant is unique in ALS research because of its relative abundance and the opportunities of C9ORF72 related research are only just beginning to be understood. By investing early a prominent future impact is secured. 
The application is aligned with major elements of the UK National Strategic Agenda as outlined in reviews and reports from Government Departments and Non-Departmental Public Bodies: 
- HM Treasury Comprehensive Spending Review 2007 - 'Better Care for All' and 'Better Health and Wellbeing For All' through a 'molecules to bedside' approach to biomedical research.
- NIHR Agenda 2006 -'Best Research for Best Health' developing international research excellence in the UK. 
-Neurodegenerative diseases and ageing are key strategic research priorities for MRC and NIHR. 
- HM Treasury 2007 (The Sainsbury Review) defined UK science/innovation goals and objectives: encouraging diversity of excellence among HEIs; developing global leadership; enhancing capacity; developing the regional spend on science and innovation. 
- Joint HM Treasury/DTI/DES 2004-2014 Science and Innovation Investment Framework objectives: building world class UK centres of research excellence to support growth in internationally mobile R&amp;amp;D and highly skilled people. 
-The Department for Business, Innovation and Skills Strategy for Life Sciences 2011. The project is aligned with key elements of this strategy including: attracting, developing and rewarding talent; Identifying targeted groups of patients to give better diagnostic tools and greater certainty about therapeutic response; and linking academia with the NHS and disease charities, with the potential for the development of partnerships with industry.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>192130</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biosciences</gtr:department><gtr:description>Collaboration to Perform Southern Blotting for Sizing of the GGGGCC Repeat Expansion of C9ORF72</gtr:description><gtr:id>FE851DAF-73E0-4B33-B6BC-F7B5ECE8B348</gtr:id><gtr:impact>Two papers published thus far: 23587638, 23566336. A further paper in-press and another under preparation.</gtr:impact><gtr:outcomeId>nA2U68bMo58-1</gtr:outcomeId><gtr:partnerContribution>Prof Buchman designed the Southern probe. I obtained samples, performed the Southern blots and carried out data analysis.</gtr:partnerContribution><gtr:piContribution>Two papers published thus far: 23587638, 23566336. A further paper in-press and another under preparation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MNDA Sheffield Branch AGM speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AE78F190-40EC-4EF9-A1A8-BAC3839BCA2C</gtr:id><gtr:impact>30 patients and family members attended a talk about my research. Interesting discussion about newly discovered genetic variants of MND.

Significant interest expressed in research involvement.</gtr:impact><gtr:outcomeId>iLcwJurSJNc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Blackpool Spring Conference Invited Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>815AC8BF-9824-4956-97C7-AD35256A8402</gtr:id><gtr:impact>200 patients and family members attended a talk about my research. Questions and discussion followed particularly with regard to future therapies.

I was able to resolve uncertainty about MND for concerned patients and families.</gtr:impact><gtr:outcomeId>SPio6ZuhrkE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.mndassociation.org/Resources/MNDA/News/Documents/Spring%20conference%20Programme.pdf</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Yorkshire Dales Branch AGM Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C09CDE54-1488-4C18-BACF-20414E80D3AB</gtr:id><gtr:impact>30 patients and family members attended a talk about my research. Discussion afterwards focused on changing understanding of the genetics of MND.

Ongoing fundraising by Yorkshire Dales Branch of the MNDA</gtr:impact><gtr:outcomeId>FQx6JsDmCsv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR Clinical Lectureship</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>427CBBA9-EF11-4DFC-BF83-34DD19865FE1</gtr:id><gtr:outcomeId>56dda05c76b409.72109395</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Optomised protocol of Southern blot hybridisation for sizing of C9ORF72 repeat expansions.</gtr:description><gtr:id>175162A7-AFC0-4929-ACB9-F0744E597EE8</gtr:id><gtr:impact>Two papers published thus far: 23587638, 23566336. A further paper in-press and another under preparation.</gtr:impact><gtr:outcomeId>nJ6MCw7p5Dn</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Probe for Southern</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>376F824F-B6CA-4167-951E-2F728DB33A9C</gtr:id><gtr:title>C9ORF72 transcription in a frontotemporal dementia case with two expanded alleles.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>544f89cca54650.85479576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BBCFACF-03B6-4044-B609-BA52E3042279</gtr:id><gtr:title>Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeat.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189b1ab3fec05c8e5670388f3356335d"><gtr:id>189b1ab3fec05c8e5670388f3356335d</gtr:id><gtr:otherNames>Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_22869_29_23587638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FBFAD44-E5C3-4E9B-80BD-258AA22D62A8</gtr:id><gtr:title>The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>544f89cd4a2a64.57069082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30561882-C399-4503-AA51-B79E17D1FB25</gtr:id><gtr:title>Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544f89cde0f513.07547679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A98D6650-7469-4C37-9E73-76126FB90A0C</gtr:id><gtr:title>Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035fd6446ad51dcfd45eac40f171f90d"><gtr:id>035fd6446ad51dcfd45eac40f171f90d</gtr:id><gtr:otherNames>Highley JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>544f89cdb09ad8.57631649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14660E6D-1DDD-4C40-91D6-1AD27D39CCD1</gtr:id><gtr:title>C9ORF72 expansions, parkinsonism, and Parkinson disease: a clinicopathologic study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_22869_29_23884045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BF3115C-2A92-42C5-8BFB-A4F4B02EA922</gtr:id><gtr:title>TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/097fa5ac687e318ffb9ff4b6418aefdc"><gtr:id>097fa5ac687e318ffb9ff4b6418aefdc</gtr:id><gtr:otherNames>Gallagher MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>544f89ccd679c0.74212516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F24D42E-EDEC-4A9C-84E8-69AF65FCFE7E</gtr:id><gtr:title>Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7a2d9405adbdec6ffa1d89cdb95f6a8"><gtr:id>d7a2d9405adbdec6ffa1d89cdb95f6a8</gtr:id><gtr:otherNames>Walsh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>544f89ce1ac251.23410168</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04B4C538-C06F-45F4-9EC7-EB472E287DBA</gtr:id><gtr:title>Concurrent amyotrophic lateral sclerosis and cystic fibrosis supports common pathways of pathogenesis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4bfae792d5ae9491325012d23555157"><gtr:id>e4bfae792d5ae9491325012d23555157</gtr:id><gtr:otherNames>Lo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_22869_29_23286748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7D936CA-559F-44BE-9ACB-1FA5A0643FD4</gtr:id><gtr:title>Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da5399d7379fab45c277ca7aace088c5"><gtr:id>da5399d7379fab45c277ca7aace088c5</gtr:id><gtr:otherNames>Ismail A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_22869_29_23085936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>123BA34A-7877-4137-8396-0EE73C200C76</gtr:id><gtr:title>C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675e54d1f89e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FF1CAB3-7E15-470D-BCAC-B42E603E0850</gtr:id><gtr:title>C9ORF72 hexanucleotide repeat expansion in ALS patients from the Central European Russia population.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b78790fb782fe3ad4dff45dab12ae4fa"><gtr:id>b78790fb782fe3ad4dff45dab12ae4fa</gtr:id><gtr:otherNames>Abramycheva NY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5675e9f6350c2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0C2964D-41A7-4D7A-BEC9-47C960469999</gtr:id><gtr:title>Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_22869_29_22366792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77409FCF-585E-4D43-AA14-E77553A6C490</gtr:id><gtr:title>The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1878-7479</gtr:issn><gtr:outcomeId>5675e04ce7d22</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F77323B5-9F16-41EF-B03F-229F3D025BCD</gtr:id><gtr:title>Simultaneous and independent detection of C9ORF72 alleles with low and high number of GGGGCC repeats using an optimised protocol of Southern blot hybridisation.</gtr:title><gtr:parentPublicationTitle>Molecular neurodegeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/589672c44739bd941875c178cd20ebb0"><gtr:id>589672c44739bd941875c178cd20ebb0</gtr:id><gtr:otherNames>Buchman VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-1326</gtr:issn><gtr:outcomeId>pm_22869_29_23566336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F82A14D7-6C3E-46A0-928D-C66DC32CB7C9</gtr:id><gtr:title>Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>5675e3d49eb59</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88DC0AA9-11BA-4331-89FD-394072520114</gtr:id><gtr:title>Pulsatile exposure to simulated reflux leads to changes in gene expression in a 3D model of oesophageal mucosa.</gtr:title><gtr:parentPublicationTitle>International journal of experimental pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/874b24d46914c3abb4c041bdd0436768"><gtr:id>874b24d46914c3abb4c041bdd0436768</gtr:id><gtr:otherNames>Green NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-9673</gtr:issn><gtr:outcomeId>544f89cd760921.74997667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4963C4A8-12CB-4E8E-8F01-2AFDA7A18E00</gtr:id><gtr:title>Gene expression profiling in human neurodegenerative disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>pm_22869_29_22890216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71665799-924F-4013-AB26-7CAA8F1BD5F9</gtr:id><gtr:title>Neurodegeneration caused by intronic expansions of C9ORF72 is a clinically heterogeneous but pathologically distinct disease</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_22869_13_60472_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE2F590D-FD90-4CBF-A318-FF678178BDDC</gtr:id><gtr:title>Comparison of blood RNA extraction methods used for gene expression profiling in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af15fffd81b453968ad48d3102ce6df"><gtr:id>1af15fffd81b453968ad48d3102ce6df</gtr:id><gtr:otherNames>Bayatti N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544f89cd171057.80114713</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0527640-F217-42C5-9B71-8DD8B9446658</gtr:id><gtr:title>Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035fd6446ad51dcfd45eac40f171f90d"><gtr:id>035fd6446ad51dcfd45eac40f171f90d</gtr:id><gtr:otherNames>Highley JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>585d6ef37f0d68.75677579</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K003771/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>